Mutations in microRNA-96 (MIR96) cause autosomal dominant deafness-50 (DFNA50), a
form of delayed-onset hearing loss. Genome editing has shown efficacy in hearing recovery …

A recent study published in Science Translational Medicine by Xiao et al. reported the use of
mini dCas13X-based adenosine base editor (mxABE) to correct a mutant transcript and …

Programmable RNA editing tools enable the reversible correction of mutant transcripts,
reducing the potential risk associated with permanent genetic changes associated with the …

Abstract CRISPR/RfxCas13d (CasRx) editing system can specifically and precisely cleave
single-strand RNAs, which is a promising treatment for various disorders by downregulation …

Background Aging, noise, infection, and ototoxic drugs are the major causes of human
acquired sensorineural hearing loss, but treatment options are limited. CRISPR/Cas9 …

Outer hair cell (OHC) degeneration is a major cause of progressive hearing loss and
presbycusis. Despite the high prevalence of these disorders, targeted therapy is currently …

Hereditary hearing loss (HHL) is a neurosensory disorder that affects every 1/500 newborns
worldwide and nearly 1/3 people over the age of 65. Congenital deafness is inherited as …

Myosin VI (MYO6) is an unconventional myosin that is vital for auditory and vestibular
function. Pathogenic variants in the human MYO6 gene cause autosomal-dominant or …

Targeted genome editing mediated by clustered, regularly interspaced, short palindromic
repeat (CRISPR)/CRISPR-associated nuclease 9 (Cas9) technology has emerged as one of …

CRISPR/Cas9 gene editing enables the treatment of hearing loss in congenitally deaf
neonatal mice via both viral and non-viral delivery. While adeno-associated virus (AAV) …